Melbourne, April 26, 2026, 23:01 (AEST)
- CSL bought back 101,810 shares on April 23, its latest ASX filing showed.
- The repurchase landed after Reuters reported CSL’s stock had touched its lowest level since 2017.
- Investors are weighing the buyback against weaker U.S. flu-shot demand and a still-unfinished earnings reset.
CSL Limited pushed ahead with its on-market share buyback, purchasing 101,810 shares on April 23 for A$13.1 million, even as the Australian biotech group’s stock trades under fresh pressure from a U.S. military policy change that could hurt flu vaccine demand. The filing, dated April 24, showed the shares were bought at prices between A$127.98 and A$129.98.
The timing matters. CSL is trying to show balance-sheet discipline after a sharp loss of investor confidence, while the market is re-marking its vaccine business after the Pentagon scrapped mandatory flu shots for U.S. service members. Reuters reported last week that CSL had fallen to its lowest level since late August 2017 and was down more than 25% this year.
CSL’s latest notice brings total shares bought back under the current program to just under 6.0 million, with cumulative consideration of about A$1.01 billion in Australian-dollar filing terms. The company said it intends to buy back up to US$750 million of ordinary shares under the program, which is scheduled to run until June 30.
The Pentagon decision is a direct hit to sentiment around CSL Seqirus, the company’s vaccine unit. Defense Secretary Pete Hegseth said U.S. military personnel would no longer be required to receive flu vaccines, while Reuters reported that Sanofi, CSL Seqirus, GSK and AstraZeneca were among vaccine makers not immediately available for comment.
“The Pentagon’s move” was a “meaningful catalyst for the sell-off,” Marc Jocum, senior product and investment strategist at Global X ETFs, told Reuters. He said it added pressure “at the worst possible time” for CSL, which was already dealing with weaker U.S. flu vaccination rates and softer Seqirus earnings. Reuters
Hebe Chen, market analyst at Vantage Markets, told Reuters the issue was broader than one policy shift, pointing to “slowing earnings momentum, a more volatile vaccine segment” and less clarity on CSL’s forward strategy. That is the nub of the problem for shareholders: the buyback may support earnings per share, but it does not by itself fix demand. Reuters
CSL’s first-half results left little room for drift. In February, the company reported underlying NPATA of US$1.9 billion, down 7%; NPATA is a profit measure that strips out amortisation of acquired intellectual property and significant one-off items. Reported net profit after tax fell 81% to US$401 million after restructuring costs and impairments, and CSL expanded the buyback from US$500 million to US$750 million.
Ken Lim, CSL’s chief financial officer, said at the time the company was “clearly not satisfied” with its performance and had an “ambitious growth plan” for the second half, driven by immunoglobulin, albumin and newer products. Immunoglobulin refers to antibody-based plasma medicines used to treat immune and other serious disorders.
The company’s core business remains CSL Behring, which makes plasma products, gene therapies and related medicines. Its other main units are CSL Seqirus, focused on influenza vaccines and pandemic services, and CSL Vifor, which sells treatments in iron deficiency and kidney disease.
CSL has also told investors that most of its U.S. product sales are not expected to be hit by planned U.S. tariffs on imported pharmaceuticals, while noting it was still working through the details. It said its U.S. plasma therapies use plasma sourced entirely in the United States, and that Fluad, the main CSL Seqirus product sold in the U.S., is made in the UK, where CSL expects the tariff rate to fall to zero.
The risk is that several pressures arrive at once. A weaker U.S. flu season, slower plasma recovery, generic competition in iron products or a less favourable tariff outcome could force CSL to lean harder on cost cuts and buybacks while investors wait for proof of earnings growth.
For now, the signal is mixed. CSL is buying its own stock near multi-year lows, but the latest repurchase is being made in a market still questioning whether one of Australia’s former growth staples can rebuild momentum fast enough.
